Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by unplugged1on Jan 14, 2024 6:51am
99 Views
Post# 35825682

RE:Tick-Tock DEA

RE:Tick-Tock DEAGreat work mdjbrown!

Federal health officials acknowledged that they conducted an analysis and found that more than 30,000 health care professionals “across 43 U.S. jurisdictions are authorized to recommend the medical use of marijuana for more than six million registered patients for at least 15 medical conditions.”

Barely a day after a government lawyer said the documents would be released in their entirety, officials made them available to Matt Zorn - the attorney who sued the government over a Freedom of Information Act request to obtain them. In October, Zorn filed a complaint in the U.S. District Court in Washington, D.C.demanding that it produce a copy of the letter issuing the cannabis scheduling review directive.

Zorn posted an image to his On Drugs blog on Friday of a letter to DEA Director Anne Milgram in which the Office of the Assistant Secretary for Health writes that “Marijuana meets the findings for control in Schedule III set forth in 21 U.S.C. 812(b)(3).”

Stay safe folks.https://t.co/ygvqVxb1Ra

:
)

 
<< Previous
Bullboard Posts
Next >>